Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...

Gilead Sciences (GILD) upgraded to Buy by Truist after raising its 2023 sales outlook. Read more here.

NEW YORK – ProteinQure said Thursday that the US Food and Drug Administration and Health Canada cleared it to begin a Phase I trial of its lead candidate, the peptide-drug conjugate PQ203, in ...

Gilead Sciences, Inc. (GILD) posted better-than-expected second-quarter 2025 results and upped its annual guidance. Adjusted earnings per share (EPS) of $2.01 beat the Zacks Consensus Estimate of ...

Gilead reported sales of its cell therapies were down 7%, with blockbuster Yescarta declining by 5% and Tecartus seeing a 14% drop-off.

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...